| Oct 17 |
With 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backing
|
| Sep 19 |
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
|
| Sep 9 |
Rezolute rises as FDA lifts clinical hold on hyperinsulinism therapy
|
| Sep 9 |
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
|
| Sep 3 |
Pleasing Signs As A Number Of Insiders Buy Rezolute Stock
|
| Aug 27 |
Rezolute to Participate in Upcoming Investor Conferences
|
| Aug 5 |
Rezolute gets FDA okay for Phase 3 ersodetug registrational study
|
| Aug 5 |
Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
|
| Jul 31 |
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
|
| Jun 27 |
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
|
